Early prediction of long-term response to natalizumab in multiple sclerosis

Conclusions Relapses and new MRI activity within the first year of starting natalizumab predict short-term outcomes, but not long-term disability outcomes. This requires further validation in other cohorts.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research